Jacobson Pharma announces strong FY2025 results, special dividend

Jacobson Pharma Corporation Limited (HKEX: 2633) announced robust financial results for the year ended March 31, 2025, driven by strong performance in specialty medicines and generic drugs. Revenue increased 7.4% year-over-year to HKD1,576.9 million, while profit from continuing operations surged 43.1% to HKD300.8 million. Building on these results, the Board recommends a final cash dividend of HKD0.055 per share and a special cash dividend of HKD0.06 per share, subject to shareholder approval at the annual general meeting on July 28, 2025. The register of members will close on August 13 and 14, 2025. Payment is expected on August 28, 2025 to shareholders registered as of August 14, 2025. Coupled with an interim dividend, the total cash dividend for FY2025 will be HKD0.15 per share. This comes after placing 66,000,000 new shares in February 2024 to broaden its shareholder base. All proceeds from this placement, totalling HKD38,898,000, have been utilized to renovate the Group's manufacturing facilities. These financial highlights reflect the company’s success through strategic growth initiatives.